HT 0712

Drug Profile

HT 0712

Alternative Names: HT-0712; IPL-455903

Latest Information Update: 29 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Developer Dart NeuroScience
  • Class Anti-inflammatories; Cyclopentanes; Nootropics; Phenyl ethers; Piperidones; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Memory disorders

Most Recent Events

  • 29 Jul 2015 Phase-II development is ongoing in USA and Europe
  • 01 Jan 2015 Dart NeuroScience completes a phase II trial in Memory disorders in USA (NCT02013310)
  • 01 Dec 2013 Phase-II clinical trials in Memory disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top